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0.7%, p¼0.9976).
Conclusion: This sub-analysis of the ORBIT II study demonstrates that males and
females treated with orbital atherectomy for severely calciﬁed coronary arteries
(generally regarded as high-risk revascularization) demonstrate similar 30-day out-
comes. In the context of the larger study, one can presume that the novel coronary
Orbital Atherectomy System is a safe and effective adjunctive therapy for severely
calciﬁed coronary lesions in both men and women.C
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Feasibility of the Use of the Tryton™ Dedicated Bifurcation Stent via the Transradial
Route - A Single Centre Experience
Ashish Shah, Muezz Uddin, Shantu Bundhoo, Richard Anderson, Tim Kinnaird
University Hospital of Wales, Cardiff, Cardiff, United Kingdom
Background: The use of the Transradial access (TR) for the treatment of Coronary
Bifurcation Lesions (CBL) with Percutaneous Coronary Intervention (PCI) can be
limited where a two stent strategy is required as larger sheath and guide catheters are
required to facilitate stent delivery. With the development of newer dedicated bifur-
cation stents, there is an increasing trend of these stents to be adopted in PCI centres
to treat CBL’s. We report our experience of the use of the Tryton dedicated side
branch bifurcation stent at our default TR centre where 90% of all PCI are carried out
via the TR.
Methods: This was a prospective study of all patients who were found suitable to
undergo PCI to CBL’s using the Tryton stent between September 2009 and June
2013. Data on patient demographics and procedure characteristics was collected from
the local hospital database.
Results: 36 patients (Male 69.4%, age 68.1 years) underwent PCI using the
19mm long Tryton bifurcation stent. Most of the CBL’s treated were located in
the LAD/Branch (52.8%), followed by the Circumﬂex/Branch (27.8%), Left
main stem/Branch (13.9%), RCA/Branch (2.7%) and LIMA graft (2.7%).
Tryton stents dimensions (Side branch/Main branch diameters) deployed were
(2.5/2.5mm - 11.1%; 2.5/3.0mm - 25%; 2.5/3.5mm - 47.2%; 3.0/3.5mm - 8.3%
and 3.5/4.0mm - 8.3%). 91.6% of cases were carried out via 6F guide catheters
with the remaining cases carried out via the 7F. Mean contrast volume, radiation
dose and ﬂuoroscopy times were 306 mls, 98.8 Gy/cm2 and 28.2 minutes
respectively. 94.4% of all cases were successfully carried out via the TR route with
remaining cases switching to the transfemoral route to successfully complete the
procedure.
Conclusions: When treating CBL’s, a wide range of Tryton dedicated side branch
stents can be safely and effectively deployed via the TR route using 6F/7F Guide
catheter systems. This can avoid the use of the transfemoral route and its associated
potential vascular complications.CABG
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Under-Utilization of Statins and Aspirin Following Coronary Artery Bypass Graft
Surgery
Kevin Curl, Bryan LeBude, Nicholas Ruggiero, David Fischman, Andrew Rose,
Sulay Patel, David Ogilby, Paul Walinsky, Babu Jasti, Michael Savage
Thomas Jefferson University Hospital, Philadelphia, PA
Background: Coronary artery bypass graft (CABG) surgery is commonly performed
to treat ischemic heart disease, but long term beneﬁts are limited by patency of
saphenous vein grafts. Both statin medications and aspirin hold class I indications for
all post-CABG patients and should be continued indeﬁnitely unless contraindication
exists. Unfortunately, there is limited data regarding long-term usage of these medi-
cations. We assessed utilization rates among post-CABG patients without docu-
mented contraindication.
Methods: A retrospective analysis of post-CABG patients presenting to the Thomas
Jefferson University cardiac catheterization laboratory for a catheterization procedure at
least 3 years after surgery was performed. Inpatient and outpatient records were
reviewed to assess prescribing patterns of these medications, as well as other pertinent
clinical and laboratory data.
Results: The study population consisted of 381 consecutive patients who presented
on average 11  6 years from the time of CABG. Mean age of our study population
was 69  11 years with 78% male. The most common indications for catheterization
were unstable angina (36%), non-STEMI (22%), and an abnormal stress test (15%).
Only 67% of patients were being prescribed a statin, while 75% were prescribed
aspirin. Only 52% were prescribed both at the time of catheterization. Three percent
had a documented intolerance to statin therapy. Patients prescribed a statin had a
signiﬁcantly lower mean LDL (87 vs. 106 [p<0.01]) and total cholesterol values (151
vs. 162 [p<0.01]). Thirty ﬁve percent of patients had LDL  100. Only 43% of
saphenous vein grafts among the patients not on statin medications remained patent
an average of 11 years post-CABG surgery.
Conclusions: Long-term statin and aspirin use following CABG surgery remains
suboptimal despite clear guideline recommendations and clinical trial evidence of their
effectiveness. Coordinated efforts are needed to improve long-term medication usage
in this subset of high risk patients.
Cardiovascular Pharmacology
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Omeprazole Use is Associated with Increased Cardiovascular Complications in Asian
Patients on Aspirin and Clopidogrel After Percutaneous Coronary Intervention
Min Sen Yew, Poh Shuan Daniel Yeo, Jau Lueng Paul Ong, Lijuan Mira Shen,
Hee Hwa Ho, Fahim Haider Jafary, Yau Wei Ooi, Kwok Kong Jason Loh,
Ko Beng Julian Tan, Chee Guan David Foo
Tan Tock Seng Hospital, Singapore, Singapore
Background: Dual anti-platelet therapy (DAPT) with Aspirin and a Thienopyridine-
derivative P2Y12 Inhibitor (commonly Clopidogrel) is mandatory after Percutaneous
Coronary Intervention (PCI). H2 receptor antagonists (H2RA) or Proton Pump
Inhibitors (PPI) are prescribed to reduce gastrointestinal bleeding risk.
